BNR SEC Filing News — Burning Rock Biotech Limited

Latest SEC filings for Burning Rock Biotech Limited (BNR) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-07-02.

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast c…
Sector: Healthcare Industry: Diagnostics & Research Market Cap: $124.7M CIK: 1792267
2
Total Filings
2
Bullish Classifications
0
Bearish Classifications
2
Insider Transactions
0
Material Events (8-K)
0
Periodic Reports
Rule-based classifications for BNR currently lean bullish. Of the 2 displayed SEC filing records, 2 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 2 insider transactions (Form 4) in this period.
Insider Transactions 2 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 2 filings in this group are Form 4s for Burning Rock Biotech Limited.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 2 insider filings shown, the breakdown is 2 open-market purchase. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market purchase ×2
The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.
Form 4 Open-market purchase Insider Buying 2026-07-02

BNR insider Han Yusheng (Director) bought 731,410 shares (~$6.18M)

Han Yusheng, listed as Director at Burning Rock Biotech Ltd, reported an open-market purchase of 731,410 BNR shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 24,760 $8.74 $216.4K
P Open-market purchase 210,000 $9.25 $1.94M
P Open-market purchase 111,110 $9.00 $1000.0K
P Open-market purchase 104,650 $7.45 $779.7K
P Open-market purchase 5,990 $7.50 $44.9K
P Open-market purchase 250,000 $8.00 $2.00M
P Open-market purchase 24,900 $8.00 $199.1K
Filing: Form 4 (Insider Transaction) Insider: Han Yusheng (Director) Shares: 731,410 Est. Value: $6.18M
View on SEC EDGAR → Open Filing Document →
Form 4 Open-market purchase Insider Buying 2026-04-02

BNR insider Han Yusheng (Director) bought 314,870 shares (~$5.47M)

Han Yusheng, listed as Director at Burning Rock Biotech Ltd, reported an open-market purchase of 314,870 BNR shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code Nature Shares Price Value
P Open-market purchase 314,870 $17.36 $5.47M
Filing: Form 4 (Insider Transaction) Insider: Han Yusheng (Director) Shares: 314,870 Est. Value: $5.47M
View on SEC EDGAR → Open Filing Document →

How we classify Burning Rock Biotech Limited's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on BNR. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — BNR SEC Filings

More Tools for BNR

BNR Full Stock Analysis BNR Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper BNR analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the BNR stock analysis page.

BNR Full Analysis
Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.
Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer